MAIA Biotechnology Provides Positive Phase 2 Clinical Updates for Lead ...
MAIA Biotechnology reports positive Phase 2 trial results for THIO in NSCLC, showing unprecedented disease control rates. The company outlines 2024 milestones, including advancing THIO-101 trial and developing next-gen telomere-targeting agents. THIO, a first-in-class telomere-targeting agent, is in clinical development for NSCLC, with promising efficacy and safety data.
Related Clinical Trials
Reference News
MAIA Biotechnology Provides Positive Phase 2 Clinical Updates for Lead ...
MAIA Biotechnology reports positive Phase 2 trial results for THIO in NSCLC, showing unprecedented disease control rates. The company outlines 2024 milestones, including advancing THIO-101 trial and developing next-gen telomere-targeting agents. THIO, a first-in-class telomere-targeting agent, is in clinical development for NSCLC, with promising efficacy and safety data.